Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Oncologie Enters $126 Million Deal for China Rights to Cancer Drug

publication date: Feb 15, 2018

Oncologie Inc., a Boston-Shanghai biopharma, in-licensed greater China rights to lefitolimod, an immunoncology candidate developed by Mologen of Berlin. The two companies also plan a global collaboration for lefitolimod, including a biomarker that Oncologie will develop. Oncology will make an initial $3.7 million payment and invest another $2.5 million in Mologen's shares within one year. In addition, Oncology agreed to pay milestones that total over $120 million plus double-digit royalties on any sales. The two companies will share revenues from any sales, based on their contributions. More details....

Stock Symbol: (F: MGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.